ClinicalTrials.gg
Drug

Ivonescimab clinical trials

Also written AK112 and SMT112.

studies test it
146
open now
118
in phase 3
16
first study started
2010

How each study uses ivonescimab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the ivonescimab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
Not in FDA's approval records
European Union
Not in EMA's list of EU-wide authorizations

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Ivonescimab
55
Ivonescimab Combined With Chemotherapy
6
Anti-PD-1/Anti-VEGF Bispecific Antibody AK112
6
Anti-PD-1/VEGF Bispecific Antibody AK112
6
PD-1/VEGF Bispecific Antibody AK112
6

Development codes

AK112
59
SMT112
11

Studies by the year they started

142 studies that test it; most in 2025 (59); 4 more planned to start later

Studies that test ivonescimab, by start year
YearStudies
20101
20191
20201
20215
20229
20238
202421
202559
202637

Who runs them

Industry 47 · Other 99

Akeso (38) · M.D. Anderson Cancer Center (9) · Sun Yat-sen University (8) · Fudan University (6) · Summit Therapeutics (5) · Memorial Sloan Kettering Cancer Center (5) · Tianjin Medical University Cancer Institute and Hospital (4) · Peking University Cancer Hospital & Institute (3)

Often tested with

Tested in the same studies.

Cadonilimab (8) · Docetaxel (6) · Ligufalimab (5) · Paclitaxel (4) · Gemcitabine (4) · Albumin-Bound Paclitaxel (3) · Trastuzumab rezetecan (3) · Irinotecan sucrosofate (2)

Related medicines

As reviewed, each with the page that says it.

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Reaching primary completion within a year · 46, 5 in phase 3

Studies that test ivonescimab, phase 3 first.

Studies

Open first, then newest update. How each study uses ivonescimab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 146

See all 146 studies that test ivonescimab →

Given beside what is tested · 21 — ivonescimab is usual care or a partner of the new treatment

Showing 20 of 21.

As the comparator · 1 — what is tested is compared with ivonescimab

Codes

What other systems call ivonescimab · ClinicalTrials.gg INT018524

  • UNII (FDA) Y0O332CU66IVONESCIMABOne source FDA
  • NCI Thesaurus C184865IvonescimabOne source FDA

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.